Ferring BV v Pure Health Direct Pty Ltd

Link copied
Case Copied 31 min read

TRADE MARKS ACT 1995



DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS WITH REASONS

Re:Opposition by Ferring BV to registration of trade mark application 1299321(5) - MEDIPURE – proceeding in the name of Pure Health Direct Pty Ltd.

Delegate: Iain Thompson
Representation: Opponent: Ben Fitzpatrick of Counsel, instructed by Dawn Logan Keeffe of Davies Collison Cave.
Applicant: Written submissions by Cullen & Co
Decision: 2011 ATMO 99
S52 opposition: sections 44, 58 and 59 – no ground established

Background

  1. This matter arises out of the filing of an application to register a trade mark which proceeds in the name of Pure Health Direct Pty Ltd[1] (‘the applicant’) of Clontarf, Queensland.  Current details of this application are:

    Application No:           1299321
    Priority Date:               15 May 2009

    Goods:Class 5:  Dietetic substances adapted for medical use including dietetic foods and drinks; dietetic foods for use in conjunction with sports nutrition; dietetic foodstuffs and substances for invalids; functional foods being medicinal food having health promoting and/or disease-preventing property beyond basic nutrition; food for babies; food supplements for medical purposes; health food supplements made principally of minerals; health food supplements made principally of vitamins; medicated food supplements; medicated preparations for use as supplements for food; medicated supplements for food; medicated supplements for foodstuffs for human consumption; mineral dietary supplements for humans; mineral food-supplements; mineral supplements for foodstuffs for human consumption; mineral supplements to foodstuffs; nutritional supplements; nutritional supplements for medical use; fish and krill oils being nutritional supplements; plant compounds for use as dietary supplements (medicinal); herbal dietary supplements for special dietary requirements; supplements (trace element) for foodstuffs for human consumption; vitamin preparations in the nature of food supplement; vitamin supplements; vitamin supplements for foodstuffs for human consumption; protein foods for human consumption (adapted for medical purposes); protein preparations for use as additives to foodstuffs for human consumption (adapted for medical purposes); protein products for human consumption (adapted for medical purposes); aromatic teas (for medicinal use); herbs teas for medicinal purposes; sun screening preparations for medical purposes; suntanning preparations for medical use; sun skin care products for medical purposes

    Trade Mark:                MEDIPURE

    [1] The application was filed by Yogie Lite Pty Ltd and the assignment of the trade mark to the applicant was recorded on 15 April 2010.

  2. The application was examined in compliance with section 31 of the Trade Marks Act 1995 (‘the Act’) and advertised as accepted for possible registration in the Australian Official Journal of Trade Marks on 12 November 2009.

  3. On 15 February 2010, after seeking and receiving an extension of time in which to do so, Ferring BV (‘the opponent’) of Hoofddorp, The Netherlands, served and filed Notice of Opposition (‘the Notice’) to the registration of the trade mark. The Notice includes all of the available grounds of opposition including those under sections 44, 58 and 59 which were subsequently argued at a hearing.

  4. The hearing was before me as a delegate of the Registrar of Trade Marks in Sydney on 9 August 2011.  Mr Ben Fitzpatrick…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Ferring BV v Pure Health Direct Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2011] ATMO 99
Decision Date

CaseChat Overview and Summary

This matter concerned an opposition by Ferring BV to the trade mark application by Pure Health Direct Pty Ltd. The hearing was conducted by Iain Thompson, a delegate of the Registrar of Trade Marks. The opponent was represented by counsel, while the applicant, who did not appear at the hearing, relied on written submissions.

The primary legal issue before the delegate was whether the opponent had established any grounds for opposing the registration of the applicant's trade mark. The opponent's evidence focused on its own trade mark, MENOPUR, and its use in the biopharmaceutical field, particularly in reproductive health. The opponent sought to demonstrate that its prior use and registration of MENOPUR internationally, and its efforts to register the mark in Australia for fertility-stimulating hormones, constituted grounds for opposition.

The delegate considered the evidence presented, including statutory declarations detailing the global registration and use of the MENOPUR trade mark by Ferring BV and its associated companies. However, the delegate noted that the opponent's evidence established that the goods for which MENOPUR was intended to be sold in Australia were not formally on the market at the priority date of the opposed application. Crucially, the delegate found that the opponent had not established a ground of opposition.

Consequently, the delegate decided to allow the trade mark application to proceed to registration, subject to the usual one-month period for appeal. The delegate also awarded costs to the applicant, as they were successful in the proceedings, to be assessed on the official scale.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

The hearing was before me as a delegate of the Registrar of Trade Marks in Sydney on 9 August 2011. Mr Ben Fitzpatrick of Counsel instructed by Ms Dawn Logan Keeffe of Davies Collison Cave represented the opponent. The applicant did not appear at the hearing and relied on brief written submissions by its attorneys, Cullen & Co.The Evidence The evidence served and filed in support of the opposition comprises statutory declarations by:Jean Marie Duvall dated 7 June 2010 with exhibits JMD-1 and JMD-2.Wendy Susan Burnett dated 12 August 2010 with exhibit WSB-1 The applicant has not served and filed evidence in answer. The opponent also served and filed further evidence, this being a statutory declaration by each of:Anna MacIntyre dated 17 August 2010 with exhibit AM-1Dawn Heaney Kirkbride Logan Keeffe declared on 4 April 2011 with exhibits A to G Wendy Susan Burnett is Special Counsel of Norton Rose Australia who then acted for the opponent. Her Declaration brings into evidence details of the Australian registration of the opponent’s trade mark MENOPUR and various Internet websites which feature the opponent’s trade mark MENOPUR. Jean Marie Duvall is General Counsel of the opponent. This Declaration explains that the Ferring group of companies (‘GOC’) to which the opponent belongs are research-driven biopharmaceutical companies, devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis Jean Marie Duvall continues by explaining:In the mid 1900s, [the GOC] developed a pharmaceutical which is a “fertility stimulating hormone”. The name chosen as a brand name in order to market this pharmaceutical was MENOPUR. This trade mark has been registered throughout the world in a number of countries in the name of [the opponent] which is the owner of this trade mark throughout the world. Now shown to me and marked exhibit JMD-2 is a list of all trade mark registrations for MENOPUR throughout the world and accompanying country code list. To the extent that other members of [the GOC] use the trade mark MENOPUR throughout the world, such use is with the authorisation of and under the control of [the opponent]. Anna MacIntyre is the Managing Director of Ferring Pharmaceuticals Pty Ltd (‘FP’) which is part of the GOC and an Australian subsidiary of the opponent. Ms MacIntyre states:On 13 February 2003 FP applied to the Therapeutic Goods Administration (TGA) to register goods to be sold in Australia under the trade mark MENOPUR. That application was withdrawn in 2004 and resubmitted in 2009 because of the need to provide additional information. Evaluation of the application is ongoing. A decision on the application is expected in early 2011 according to TGA’s current tracking system. The Declaration thus establishes that the goods proposed to be sold under trade mark MENOPUR were not formally ‘on the market’ within Australia at the priority date of the opposed application – 15 May 2009. Ms MacIntyre in the balance of her Declaration attests to the use of the trade mark MENOPUR by the opponent or under its aegis overseas.

Decision

Reasons for decision

Section 55 of the Act relevantly provides:55Decision(1)Unless the proceedings are discontinued or dismissed, the Registrar must, at the end, decide:(a)to refuse to register the trade mark; or(b)to register the trade mark (with or without conditions or limitations) in respect of the goods and/or services then specified in the application;having regard to the extent (if any) to which any ground on which the application was opposed has been established.Note:For limitations see section 6. The opponent has not established a ground of opposition. The trade mark application may then proceed to registration one month from the date of this decision. If the Registrar has been served with a notice of appeal before that time, I direct that registration shall not occur until the appeal has been decided or discontinued and that the disposition of the application be in accordance with the Court’s order or direction.Costs Having been successful in this matter, the applicant is entitled to its costs which I award against the opponent at the official scale.Iain ThompsonHearing OfficerTrade Marks Hearings13 October 2011

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.